Skip Navigation



Annals of Oncology Advance Access published online on July 24, 2009
Annals of Oncology, doi:10.1093/annonc/mdp309
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Pulte, D.
Right arrow Articles by Brenner, H.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pulte, D.
Right arrow Articles by Brenner, H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

Expected long-term survival of patients diagnosed with acute myeloblastic leukemia during 2006–2010

D. Pulte1,2,*, A. Gondos1 and H. Brenner1

1 Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany
2 Department of Medicine, Division of Hematology–Oncology, University of Medicine and Dentistry of New Jersey, Newark, NJ, USA

* Correspondence to: Dr D. Pulte, Division of Hematology–Oncology, University of Medicine and Dentistry of New Jersey, 185 South Orange Avenue, MSB I-689, Newark, NJ 07101, USA. Tel: +1-973-972-5034; Fax: +1-973-972-2384; E-mail: pultedi{at}umdnj.edu

Background: Treatment of acute myeloblastic leukemia (AML) has evolved over the past several decades. Therefore, currently available estimates of long-term survival, which are based on survival for patients treated with potentially now obsolete protocols, may not pertain to patients currently diagnosed.

Methods: Using data from the 1973–2005 database of the Surveillance, Epidemiology, and End Results Program, we empirically validated a novel model-based method to project 5- and 10-year relative survival of AML patients and we applied the method to project relative survival of AML patients in the United States diagnosed during 2006–2010.

Results: Empirical evaluation indicated that the modeling approach provides more accurate estimates of currently diagnosed patients than standard methods of survival analysis, such as cohort analysis or period analysis, in the majority of cases. Projected figures for 2006–2010 show 5- and 10-year relative survival estimates of 21.4% and 18.7% for all ages combined, 62.2% and 57.4% for ages 25–34, and 60.6% and 58.1% for ages 35–44. These estimates are substantially higher than the most up-to-date estimates obtained by standard survival analysis.

Conclusion: Patients diagnosed with AML during 2006–2010 at younger ages have much higher long-term survival expectations than indicated by previously available survival statistics.

acute myeloblastic leukemia, epidemiology, outcomes, period analysis, prognosis

Received for publication January 2, 2009. Revision received May 7, 2009. Accepted for publication May 8, 2009.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.